Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 Study.

Valle, Juan W; Palmer, D; Jackson, R; Cox, T; Neoptolemos, J; Ghaneh, P; Rawcliffe, C; Bassi, C; Stocken, D; Cunningham, D; O'Reilly, Derek; Goldstein, D; Robinson, B; Karapetis, C; Scarfe, A; Lacaine, F; Sand, J; Izbicki, J; Mayerle, J; Dervenis, C; Oláh, A; Butturini, G; Lind, P; Middleton, M; Anthoney, A; Sumpter, K; Carter, R; Büchler, M

Abstract

Adjuvant chemotherapy improves patient survival rates after resection for pancreatic adenocarcinoma, but the optimal duration and time to initiate chemotherapy is unknown.

Citation

Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 Study. 2014: J Clin Oncol

Journal

Journal of Clinical Oncology

URI

http://hdl.handle.net/10541/312409

DOI

10.1200/JCO.2013.50.7657

PubMed ID

24419109

Type

Article

Language

ISSN

1527-7755

Collections

All Christie Publications

Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 Study.

Authors

Issue Date

Metadata